Holl R W, Wolf A, Thon A, Bernhard M, Buck C, Missel M, Heinze E, von der Hardt H, Teller W M
Department of Pediatrics I, University of Ulm, Germany.
J Pediatr Gastroenterol Nutr. 1997 Aug;25(2):188-93. doi: 10.1097/00005176-199708000-00010.
Impaired glucose tolerance and secondary diabetes are frequent in older patients with cystic fibrosis (CF), associated with increased frequency of infections and reduced life expectancy. Studies on the pathophysiology of islet cell secretion in CF are a prerequisite for a scientifically based therapeutic approach.
Oral glucose tolerance tests were performed in 71 patients (14.2 +/- 0.5 years; mean +/- SE) and 56 control subjects (16.5 +/- 0.9 years). Glucose, insulin, C-peptide, and proinsulin were measured every 30 min.
Glucose tolerance in CF patients was classified as normal (NGT, n = 48), impaired (IGT, n = 14), or diabetic (DM, n = 9). Even in CF patients with NGT, blood glucose was significantly elevated at 30, 60, and 90 min of the test. Surprisingly, the secretory responses of insulin and C-peptide were not reduced in CF patients with IGT or DM compared with both healthy controls or CF patients with normal glucose tolerance. However, peak insulin concentration was reached at 90 min in CF-IGT or CF-DM patients compared with 30 min in controls. The ratio of glucose to insulin, an indicator of insulin resistance, increased in CF patients with progression of carbohydrate intolerance. Proinsulin was significantly reduced in all CF patients compared with controls (p < 0.001; Wilcoxon's rank sum test).
In CF patients with impaired glucose tolerance or diabetes, integrated insulin release is not diminished, indicating that insulin resistance is likely to contribute to hyperglycemia in CF patients with IGT or DM. Reduced proinsulin levels in CF patients are compatible either with enhanced conversion of proinsulin to insulin in compensation for reduced beta-cell mass, or enhanced clearance of proinsulin.
糖耐量受损和继发性糖尿病在老年囊性纤维化(CF)患者中很常见,与感染频率增加和预期寿命缩短有关。对CF患者胰岛细胞分泌的病理生理学研究是基于科学的治疗方法的先决条件。
对71例患者(14.2±0.5岁;均值±标准误)和56例对照者(16.5±0.9岁)进行口服葡萄糖耐量试验。每30分钟测量一次葡萄糖、胰岛素、C肽和胰岛素原。
CF患者的糖耐量分为正常(NGT,n = 48)、受损(IGT,n = 14)或糖尿病(DM,n = 9)。即使在糖耐量正常的CF患者中,试验30、60和90分钟时血糖也显著升高。令人惊讶的是,与健康对照者或糖耐量正常的CF患者相比,IGT或DM的CF患者胰岛素和C肽的分泌反应并未降低。然而,CF-IGT或CF-DM患者在90分钟时达到胰岛素峰值浓度,而对照者在30分钟时达到。随着碳水化合物不耐受的进展,CF患者中葡萄糖与胰岛素的比值(胰岛素抵抗指标)增加。与对照者相比,所有CF患者的胰岛素原均显著降低(p < 0.001;Wilcoxon秩和检验)。
在糖耐量受损或糖尿病的CF患者中,胰岛素的整体释放并未减少,这表明胰岛素抵抗可能导致IGT或DM的CF患者出现高血糖。CF患者胰岛素原水平降低,要么与胰岛素原向胰岛素的转化增强以补偿β细胞量减少有关,要么与胰岛素原清除增强有关。